Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Abstract Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemis...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2017-04-01
סדרה:	Genome Medicine
נושאים:	Tumor mutational burden Cancer genomics Mismatch repair PMS2
גישה מקוונת:	http://link.springer.com/article/10.1186/s13073-017-0424-2
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!